Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522476 | 0.89 | MRGPRX2 (0.78) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| SCHEMBL12143747 | 0.87 | MRGPRX2 (0.72) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| SCHEMBL29459625 | 0.87 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| SCHEMBL5108263 | 0.87 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Hydrochloric Acid SCHEMBL8168636 | 0.86 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| SCHEMBL5108293 | 0.85 | MRGPRX2 (0.77) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| SCHEMBL8591636 | 0.83 | MRGPRX2 (0.67) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Codeine SCHEMBL3257 | 0.80 | OPRD1 (1.00) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Codeine SCHEMBL1560699 | 0.80 | OPRD1 (1.00) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Codeine SCHEMBL21077535 | 0.80 | OPRD1 (1.00) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972332-B1 | Process for the production of opiates | ACURA PHARMACEUTICALS, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050261500-A1 | PROCESS FOR THE PRODUCTION OF OPIATES | SCHUTTE, JOHN | 2005-11-24 | — | — | US | disclosed |
| US-6949645-B1 | Process for the production of opiates | ACURA PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261500-A1 | PROCESS FOR THE PRODUCTION OF OPIATES | OPRM1, OPRK1, POP1 | MRGPRX2 1648/4885OPRM1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.